An Exploratory Study of INT-747 in Patients With Type 2 Diabetes Mellitus and Presumed Nonalcoholic Fatty Liver Disease.
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2015
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Fatty liver; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Intercept Pharmaceuticals
- 26 Jan 2012 Last checked against ClinicalTrials.gov record.
- 19 Nov 2009 Results were presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
- 02 Oct 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History